You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆指升幅收窄至不足百點 惟兩大藍籌藥股/威高/華潤醫藥漲近3%-5%
阿思達克 04-09 10:47
醫藥板塊今天普遍跑贏於大市,獲大摩升價至11.2元及評級「增持」的威高股份(01066.HK)三連漲,最高見10.44元,現造10.4元,續升3.8%。華潤醫藥(03320.HK)三連彈,今天股價升破20天線(4.55元),最高見4.78元,現造4.74元,續升4.9%。

藍籌石藥(01093.HK)及中生製藥(01177.HK)繼昨天扭四連漲隨大市略為整固後,前者股價今天高見17.14元,暫受制50天線(17.3元),現造16.8元,回升3.4%;後者股價重越100天及50天線(10.97元及11.05元),最高見11.46元,現造11.22元,回升2.7%。

藥明康德(02359.HK)扭兩連跌,今天股價重越100天線(102.2元),最高見103.9元,現造102.8元,回升3.3%。

港股繼昨天吐282點或近1.2%曾略失23,900後,今早跟隨美股(昨晚全面急彈2.6%-3.4%)高開210點或0.9%,報24,181,最高見24,232遇阻,現造24,065,僅彈94點或0.4%,成交額343億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account